Navigation Links
New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes
Date:5/28/2009

SAN DIEGO, May 28 /PRNewswire/ -- Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today the launch of its Web site (http://www.EntestBio.com) to focus on new stem cell research, including a proposed research to develop a new therapeutic solution for traumatic brain injury (TBI) using autologous adipose-derived (fat) stem cells representing a potential cure. There are currently 1.5 million new cases of TBI occurring in the U.S. each year, adding to the almost 6.5 million existing cases. The Company is also pursuing research in the use of fat stem cell therapy for spinal cord injury, in which approximately 200,000 patients in the U.S. suffer from this disability.

The site also highlights the Company's progress in developing a gestational diabetes screening test, as the exclusive licensee granted by UCLA. The non-invasive, highly accurate streamline test mitigates the lengthy process of diagnoses and would more quickly treat the glucose intolerant disease, which potentially impacts 4.3 million pregnant women each year.

Along with background about types of stem cells and factoids, the new site also reviews Entest BioMedical's focus on the promising field of in vitro expansion of adult stem cells using other types of cells, such as peripheral stem cells and cord blood stem cells to treat cancer and other diseases. The R & D company is also exploring isolating hematopoietic stem cells from peripheral blood or bone marrow and differentiating them into immune cells, especially T cells.

"Our new Web site demonstrates Entest BioMedical's mission and key scientific personnel who are dedicated to discovering and developing new procedures, treatments and medical devices that improve the quality of life - leading research and technology that serve the present and help shape the future," said David Koos, Ph.D., DBA, Chairman and CEO.

About Entest BioMedical, Inc.

Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous "adipose-derived" stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Entest BioMedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
2. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
3. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
4. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
5. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
6. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
11. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)...  In Atlanta, it seems everyone has a chance to ... create an expressive and dynamic community unlike any other. The ... to it. With their newest salon in ... to carry on that tradition with a unique, fresh approach ... salon is the newest of 13 nationwide locations, each of ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):